Azenta vs Medpace
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Azenta and Medpace side by side, using each one’s latest annual report. Here is what stands out:
- Medpace is the larger business, with $2.5B of revenue in fiscal 2025 against $594M for Azenta, about 4.3 times as much.
- Medpace grew revenue faster (20.0%, against 3.6%).
- Medpace kept more of each dollar of sales as operating profit (21.1% operating margin, against −4.5%).
- Medpace turned more of its sales into free cash flow (27.0% FCF margin, against 6.5%).
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
Azenta
AZTA
1/7
Share count change
Medpace
MEDP
6/7
Revenue growth5-year growthOperating marginNet marginFCF marginReturn on equity
Side by side
Best in the row
| Latest fiscal year | AZTA FY25 | MEDP FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.7B | $19.2B |
| Revenue | $594M | $2.5B |
| Free cash flow | $38.3M | $682M |
| Net income | −$55.8M | $451M |
| Growth | ||
| Revenue growth | 3.6% | 20.0% |
| 5-year growth | 8.9% | 22.3% |
| Share count change | −13.7% | −7.8% |
| Profitability | ||
| Gross margin | 45.5% | — |
| Operating margin | −4.5% | 21.1% |
| Net margin | −9.4% | 17.8% |
| FCF margin | 6.5% | 27.0% |
| Return on capital | — | — |
| Return on equity | −3.2% | 70.2% |
| Balance sheet | ||
| Net debt | — | −$497M |
| Net debt / EBITDA | — | −0.9x |
| Dividends and buybacks | $0.0M | $917M |
| Valuation & quality | ||
| P/E | — | 37.6x |
| Piotroski F-score | — | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.